Novartis mTOR inhibitor Zortress wins US OK in liver transplant
This article was originally published in Scrip
Executive Summary
In a late-day announcement on 15 February, Novartis revealed the US FDA gave its blessing for the Swiss drug maker to market its mammalian target of rapamycin (mTOR) inhibitor Zortress (everolimus) as therapy to prevent organ rejection in adult liver transplant patients.